首页> 外文期刊>Canadian journal of gastroenterology >Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.
【24h】

Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.

机译:胃食管反流疾病的维持治疗:雷贝拉唑20 mg的持续和按需治疗的评估。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To evaluate continuous therapy (COT) and on-demand therapy (ODT) with rabeprazole 20 mg for maintenance in uninvestigated gastroesophageal reflux disease (GERD). METHODS: This randomized, open-label study enrolled 331 GERD (heartburn-predominant) patients with a pre-existing proton pump inhibitor history of one month or longer, to an acute four-week trial with 20 mg rabeprazole daily for heartburn management. Patients who achieved satisfactory heartburn control during the acute phase (three days or less of heartburn, with no more than one episode rated as moderate, and heartburn rated satisfactorily or completely controlled with minimal rescue antacid use in the seven days preceding randomization) were randomly assigned to six months of rabeprazole 20 mg given as either daily COT or daily ODT, which was initiated upon symptom recurrence and stopped upon symptom resolution. Rescue antacid usage was permitted and tracked. Primary efficacy was measured as the proportion of heartburn-free days over six months. RESULTS: For the 268 patients, the mean percentage of heartburn-free days for the COT group and for the ODT group were 90.3%+/-14.8% and 64.8%+/-22.3%, respectively (P<0.0001). COT was associated with an increased number of medication intake days (154+/-40.2) versus ODT (68+/-46.1), with less heartburn episodes observed with COT versus ODT, respectively (n=7, n=26, P<0.0001). Ninety-two per cent of COT patients and 79% of ODT patients were either 'satisfied' or 'very satisfied' with treatment. The mean usage of antacids was low and similar in both groups. COT and ODT regimens were safe and well-tolerated, with a similar incidence of adverse events. CONCLUSION: Results based on symptom assessments favour COT with rabeprazole 20 mg for maintenance therapy in patients with uninvestigated GERD; however, both therapy types are safe and acceptable treatment options for selected patients.
机译:目的:评估雷贝拉唑20 mg的持续治疗(COT)和按需治疗(ODT),以维持未经调查的胃食管反流病(GERD)。方法:这项随机开放标签研究招募了331名GERD(以烧心为主)患者,他们已有一个月或更长的质子泵抑制剂病史,并进行了一项为期4周的急性试验,每天服用20 mg雷贝拉唑以治疗烧心。随机分配在急性期(三天或更少的胃灼热,中度发作不超过1次,在随机分配前7天以最少的抗酸剂使用满意或完全控制的情况下达到满意或完全控制)的满意的胃灼热患者至6个月的雷贝拉唑20 mg,每日COT或每日ODT给药,从症状复发时开始,在症状缓解后停止。救援酸的使用被允许和跟踪。以六个月内无烧心天数的比例来衡量主要疗效。结果:对于268例患者,COT组和ODT组的无烧心天数的平均百分比分别为90.3%+ /-14.8%和64.8%+ /-22.3%(P <0.0001)。与ODT(68 +/- 46.1)相比,COT与服药天数增加(154 +/- 40.2)相关,与ODT相比,COT分别减少了胃灼热发作的发生(n = 7,n = 26,P < 0.0001)。 92%的COT患者和79%的ODT患者对治疗“满意”或“非常满意”。两组中抗酸药的平均使用量较低且相似。 COT和ODT方案安全且耐受良好,不良事件的发生率相似。结论:基于症状评估的结果有利于未经调查的GERD患者采用COT联合雷贝拉唑20 mg作为维持治疗。但是,两种治疗方式对于选定的患者都是安全且可接受的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号